Verdicts genuinely change. Free email alert the moment JDOC's does — no target price to set, unlike "Alert" above.
Whether this fund clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
JPMorgan Healthcare Leaders ETF ETF · J.P. Morgan Exchange-Traded Fund Trust
61 holdings · as of 2026-07-31 (2.5 months ago)
NON-COMPLIANT 19.51% of portfolio weight is in non-compliant holdings, over the 5% threshold.
61 holdings, 43 matched (91% of weight). Portfolio as of 2026-07-31, filed 2026-09-28. Source: SEC Form N-PORT.
0.78% of this portfolio’s income is non-permissible — weighted across holdings, computed over 69% of portfolio weight (32 of 61 holdings). The common approach purifies that proportion of income received — dividends — not of the position’s value. We report the ratio; what to do with it is a question for your own scholar.
70.4% compliant 0.0% questionable 19.5% non-compliant 9.3% unscreened
| Holding | Status | Weight | Every methodology, and the debt ratio behind it |
|---|---|---|---|
| ABBV AbbVie, Inc. | COMPLIANT | 7.85% | AAOIFIpass Usmanifail Dow Jones Islamicpass S&P Shariahpass MSCI Islamicfail MSCI Islamic M-Seriespass FTSE Shariahfail |
| LLY Eli Lilly & Co. | COMPLIANT | 7.76% | AAOIFI5.2% Usmani38.6% Dow Jones Islamic6.4% S&P Shariah6.9% MSCI Islamic38.6% MSCI Islamic M-Series6.9% FTSE Shariah38.6% |
| UNH UnitedHealth Group, Inc. | NON_COMPLIANT | 5.85% | AAOIFI20.4% Usmani23.7% Dow Jones Islamic20.4% S&P Shariah18.8% MSCI Islamic23.7% MSCI Islamic M-Series18.8% FTSE Shariah23.7% |
| MRK Merck & Co., Inc. | COMPLIANT | 4.82% | AAOIFI14.7% Usmani41.5% Dow Jones Islamic21.8% S&P Shariah20.9% MSCI Islamic41.5% MSCI Islamic M-Series20.9% FTSE Shariah41.5% |
| JNJ Johnson & Johnson | COMPLIANT | 4.82% | AAOIFI7.6% Usmani24.4% Dow Jones Islamic10.9% S&P Shariah11.7% MSCI Islamic24.4% MSCI Islamic M-Series11.7% FTSE Shariah24.4% |
| AZN AstraZeneca plc | COMPLIANT | 3.76% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| TMO Thermo Fisher Scientific, Inc. | COMPLIANT | 3.73% | AAOIFI20.5% Usmani40.3% Dow Jones Islamic23.4% S&P Shariah22.9% MSCI Islamic40.3% MSCI Islamic M-Series22.9% FTSE Shariah40.3% |
| BMY Bristol-Myers Squibb Co. | NON_COMPLIANT | 3.57% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| ABT Abbott Laboratories | COMPLIANT | 3.11% | AAOIFI19.2% Usmani31.9% Dow Jones Islamic17.6% S&P Shariah18.3% MSCI Islamic31.9% MSCI Islamic M-Series18.3% FTSE Shariah30.8% |
| CVS CVS Health Corp. | NON_COMPLIANT | 2.83% | AAOIFI61.7% Usmani30.1% Dow Jones Islamic84.9% S&P Shariah88.7% MSCI Islamic30.1% MSCI Islamic M-Series88.7% FTSE Shariah24.2% |
| RO.SW Roche Holding AG | COMPLIANT | 2.82% | AAOIFIpass Usmanifail Dow Jones Islamicpass S&P Shariahpass MSCI Islamicpass MSCI Islamic M-Seriespass FTSE Shariahpass |
| NOVO-B.CO Novo Nordisk A/S | COMPLIANT | 2.61% | AAOIFIpass Usmanipass Dow Jones Islamicpass S&P Shariahpass MSCI Islamicpass MSCI Islamic M-Seriespass FTSE Shariahpass |
| GSK GSK plc | COMPLIANT | 2.47% | AAOIFI19.2% Usmani23.6% Dow Jones Islamic10.6% S&P Shariah11.2% MSCI Islamic23.6% MSCI Islamic M-Series11.2% FTSE Shariah23.6% |
| SYK Stryker Corp. | COMPLIANT | 2.23% | AAOIFI14.6% Usmani32.2% Dow Jones Islamic11.3% S&P Shariah11.8% MSCI Islamic32.2% MSCI Islamic M-Series11.8% FTSE Shariah31.2% |
| DHR Danaher Corp. | COMPLIANT | 2.16% | AAOIFI18.2% Usmani28.8% Dow Jones Islamic17.7% S&P Shariah16.7% MSCI Islamic28.8% MSCI Islamic M-Series16.7% FTSE Shariah28.8% |
| COR Cencora, Inc. | COMPLIANT | 2.07% | AAOIFI18.9% Usmani14.0% Dow Jones Islamic20.8% S&P Shariah22.7% MSCI Islamic14.0% MSCI Islamic M-Series22.7% FTSE Shariah14.0% |
| ARGX Argenx SE | COMPLIANT | 2.06% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| ISRG Intuitive Surgical, Inc. | COMPLIANT | 1.93% | AAOIFI0.0% Usmani0.0% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.0% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| EW Edwards Lifesciences Corp. | COMPLIANT | 1.73% | AAOIFI1.4% Usmani5.1% Dow Jones Islamic1.5% S&P Shariah1.5% MSCI Islamic5.1% MSCI Islamic M-Series1.5% FTSE Shariah4.3% |
| IQV IQVIA Holdings, Inc. | NON_COMPLIANT | 1.71% | AAOIFI36.7% Usmani55.2% Dow Jones Islamic47.8% S&P Shariah44.8% MSCI Islamic54.4% MSCI Islamic M-Series44.8% FTSE Shariah53.4% |
| Teva Pharmaceutical Industries Ltd. | UNSCREENED | 1.60% | no in-house ratios for this holding |
| REGN Regeneron Pharmaceuticals, Inc. | COMPLIANT | 1.60% | AAOIFI2.4% Usmani6.5% Dow Jones Islamic3.0% S&P Shariah2.7% MSCI Islamic4.8% MSCI Islamic M-Series2.7% FTSE Shariah4.8% |
| NVS Novartis AG | COMPLIANT | 1.60% | AAOIFI12.5% Usmani25.9% Dow Jones Islamic11.8% S&P Shariah12.6% MSCI Islamic25.9% MSCI Islamic M-Series12.6% FTSE Shariah25.9% |
| BIIB Biogen, Inc. | COMPLIANT | 1.56% | AAOIFI21.2% Usmani22.5% Dow Jones Islamic27.5% S&P Shariah24.3% MSCI Islamic22.5% MSCI Islamic M-Series24.3% FTSE Shariah21.3% |
| CAH Cardinal Health, Inc. | COMPLIANT | 1.51% | AAOIFI17.8% Usmani17.7% Dow Jones Islamic24.8% S&P Shariah28.7% MSCI Islamic17.4% MSCI Islamic M-Series28.7% FTSE Shariah15.5% |
| 4502.T Takeda Pharmaceutical Co. Ltd. | NON_COMPLIANT | 1.29% | AAOIFIfail Usmanipass Dow Jones Islamicfail S&P Shariahfail MSCI Islamicpass MSCI Islamic M-Seriesfail FTSE Shariahpass |
| CNC Centene Corp. | NON_COMPLIANT | 1.19% | AAOIFI50.5% Usmani19.4% Dow Jones Islamic62.6% S&P Shariah53.4% MSCI Islamic19.4% MSCI Islamic M-Series53.4% FTSE Shariah19.4% |
| Hoya Corp. | UNSCREENED | 1.18% | no in-house ratios for this holding |
| HUM Humana, Inc. | NON_COMPLIANT | 1.16% | AAOIFI30.1% Usmani26.3% Dow Jones Islamic44.9% S&P Shariah38.8% MSCI Islamic26.3% MSCI Islamic M-Series38.8% FTSE Shariah25.3% |
| BSX Boston Scientific Corp. | COMPLIANT | 1.07% | AAOIFI19.4% Usmani27.9% Dow Jones Islamic10.0% S&P Shariah10.9% MSCI Islamic27.9% MSCI Islamic M-Series10.9% FTSE Shariah27.9% |
| 1FRE.MI Fresenius SE & Co. KGaA | NON_COMPLIANT | 1.04% | AAOIFIfail Usmanipass Dow Jones Islamicfail S&P Shariahfail MSCI Islamicpass MSCI Islamic M-Seriesfail FTSE Shariahpass |
| Insmed, Inc. | UNSCREENED | 0.97% | no in-house ratios for this holding |
| GMAB.CO Genmab A/S | COMPLIANT | 0.83% | AAOIFIpass Usmanifail Dow Jones Islamicfail S&P Shariahpass MSCI Islamicfail MSCI Islamic M-Seriespass FTSE Shariahfail |
| Sartorius AG | UNSCREENED | 0.83% | no in-house ratios for this holding |
| Dyne Therapeutics, Inc. | UNSCREENED | 0.82% | no in-house ratios for this holding |
| VRTX Vertex Pharmaceuticals, Inc. | COMPLIANT | 0.81% | AAOIFI1.6% Usmani7.2% Dow Jones Islamic1.7% S&P Shariah1.7% MSCI Islamic7.2% MSCI Islamic M-Series1.7% FTSE Shariah0.0% |
| Spyre Therapeutics, Inc. | UNSCREENED | 0.77% | no in-house ratios for this holding |
| NBIX Neurocrine Biosciences, Inc. | COMPLIANT | 0.73% | AAOIFI2.9% Usmani8.6% Dow Jones Islamic3.4% S&P Shariah3.5% MSCI Islamic8.6% MSCI Islamic M-Series3.5% FTSE Shariah0.0% |
| BBIO Bridgebio Pharma, Inc. | COMPLIANT | 0.73% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| ALNY Alnylam Pharmaceuticals, Inc. | COMPLIANT | 0.70% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| ALGN Align Technology, Inc. | COMPLIANT | 0.70% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| CRL Charles River Laboratories International, Inc. | COMPLIANT | 0.66% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| CG oncology, Inc. | UNSCREENED | 0.62% | no in-house ratios for this holding |
| ASND Ascendis Pharma A/S | COMPLIANT | 0.59% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| Alumis, Inc. | UNSCREENED | 0.57% | no in-house ratios for this holding |
| LB Pharmaceuticals, Inc. | UNSCREENED | 0.56% | no in-house ratios for this holding |
| Disc Medicine, Inc. | UNSCREENED | 0.51% | no in-house ratios for this holding |
| PTCT PTC Therapeutics, Inc. | NON_COMPLIANT | 0.49% | AAOIFI11.9% Usmani21.4% Dow Jones Islamic16.9% S&P Shariah20.0% MSCI Islamic21.2% MSCI Islamic M-Series20.0% FTSE Shariah18.2% |
| Bicara Therapeutics, Inc. | UNSCREENED | 0.44% | no in-house ratios for this holding |
| RCUS Arcus Biosciences, Inc. | COMPLIANT | 0.43% | AAOIFI3.0% Usmani12.3% Dow Jones Islamic5.9% S&P Shariah6.5% MSCI Islamic12.3% MSCI Islamic M-Series6.5% FTSE Shariah10.9% |
| Erasca, Inc. | UNSCREENED | 0.39% | no in-house ratios for this holding |
| DMRA Damora Therapeutics, Inc. | NON_COMPLIANT | 0.37% | AAOIFI0.0% Usmani0.0% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.0% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| MDT Medtronic plc | COMPLIANT | 0.35% | AAOIFI24.4% Usmani31.5% Dow Jones Islamic26.4% S&P Shariah27.4% MSCI Islamic31.4% MSCI Islamic M-Series27.4% FTSE Shariah30.2% |
| LEGN Legend Biotech Corp. | COMPLIANT | 0.31% | AAOIFI8.8% Usmani18.4% Dow Jones Islamic2.9% S&P Shariah2.3% MSCI Islamic18.4% MSCI Islamic M-Series2.3% FTSE Shariah18.4% |
| ARGX Argenx SE | COMPLIANT | 0.30% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| Sionna Therapeutics, Inc. | UNSCREENED | 0.01% | no in-house ratios for this holding |
| Japanese Yen | UNSCREENED | 0.00% | no in-house ratios for this holding |
| EURO | UNSCREENED | 0.00% | no in-house ratios for this holding |
| Swiss Franc | UNSCREENED | 0.00% | no in-house ratios for this holding |
| British Pound | UNSCREENED | 0.00% | no in-house ratios for this holding |
| Danish Krone | UNSCREENED | 0.00% | no in-house ratios for this holding |
The published standards disagree about this fund by 26 points of portfolio weight — 64.4% of it passes AAOIFI, 38.8% passes MSCI Islamic. Which number is yours depends on which standard you follow.
These bars are the financial-ratio result under each standard — debt, receivables and interest income. They do not screen what the business does, so a holding can pass every ratio here and still be questionable or non-compliant on activity. The blended verdict above accounts for both.
ratios pass on 64.4% ratios fail on 11.7% 23.2% not rated under AAOIFI
ratios pass on 42.6% ratios fail on 33.5% 23.2% not rated under Usmani
ratios pass on 58.0% ratios fail on 16.1% 25.1% not rated under Dow Jones Islamic
ratios pass on 60.4% ratios fail on 13.8% 25.1% not rated under S&P Shariah
ratios pass on 38.8% ratios fail on 36.5% 23.9% not rated under MSCI Islamic
ratios pass on 58.9% ratios fail on 15.3% 25.1% not rated under MSCI Islamic M-Series
ratios pass on 42.6% ratios fail on 31.8% 24.8% not rated under FTSE Shariah
42 of 61 listed holdings carry our own per-methodology verdicts (90% of weight). The rest hold a provider verdict with no methodology breakdown, and are counted as rated by none. Of those, 28 (60% of weight) also carry the underlying debt ratio; the rest show a verdict without the figure behind it.
| Non-compliant holding | Weight |
|---|---|
| UNH UnitedHealth Group, Inc. | 5.85% |
| BMY Bristol-Myers Squibb Co. | 3.57% |
| CVS CVS Health Corp. | 2.83% |
| IQV IQVIA Holdings, Inc. | 1.71% |
| 4502.T Takeda Pharmaceutical Co. Ltd. | 1.29% |
| CNC Centene Corp. | 1.19% |
| HUM Humana, Inc. | 1.16% |
| 1FRE.MI Fresenius SE & Co. KGaA | 1.04% |
| PTCT PTC Therapeutics, Inc. | 0.49% |
| DMRA Damora Therapeutics, Inc. | 0.37% |
Methodology breakdown computing — it will appear here on its own.
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.
JPMorgan Healthcare Leaders ETF (JDOC) is currently considered not halal (non-compliant), per our own look-through to its filed holdings. See its filed holdings and the weight breakdown below for the reasoning.
Computing the full ratio and business-activity breakdown for JDOC — this runs off the critical path so the page paints first. It will appear here on its own.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 42.70 | NEUTRAL |
| Stochastic %K (14) | 27.71 | NEUTRAL |
| CCI (20) | -68.51 | NEUTRAL |
| Williams %R (14) | -72.29 | NEUTRAL |
| MACD (12,26,9) | 0.02 | BUY |
| ROC (10) | -1.72 | SELL |
| Momentum (10) | -1.05 | SELL |
| EMA (10) | 60.30 | SELL |
| SMA (10) | 60.04 | SELL |
| EMA (20) | 60.65 | SELL |
| SMA (20) | 60.69 | SELL |
| EMA (30) | 60.90 | SELL |
| SMA (30) | 61.10 | SELL |
| EMA (50) | 60.97 | SELL |
| SMA (50) | 61.74 | SELL |
| EMA (100) | 60.29 | SELL |
| SMA (100) | 60.32 | SELL |
| EMA (200) | 59.02 | BUY |
| SMA (200) | 58.70 | BUY |
The fund will invest primarily in equity securities issued by pharmaceutical, biotechnology, healthcare services, healthcare technology, medical technology and life sciences companies which the adviser believes are leaders and where the magnitude and/or duration of future growth for these companies is underappreciated by the market. Under normal circumstances, the fund invests at least 80% of its assets in the equity securities of healthcare companies.
Background via Yahoo Finance — informational, not part of the verdict.
No real edge — avoid
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | RANGING | 41 |
Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.
How the rest of the sector moved over the same window. Context for a price move, never a cause of one.
Peer movement computing — it will appear here on its own.
The questions worth asking about any verdict on this page, answered plainly.
No. HTR reads the fund's filed holdings and screens each one, then reports the result by weight. A fund marketed as Islamic still gets the same look-through as any other.
It is the share of the fund whose holdings HTR cannot cover far enough to rate. It is reported as unrated rather than counted as compliant, because a holding nobody screened should not look like one that passed.
It matters, and it is noted, but it does not replace the look-through. The board's judgement and the holdings screen are shown separately so you can see when they agree and when they do not.
When the fund files new holdings, and on a rolling basis besides. The date on the verdict above is the last time this fund was actually recomputed.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.
NO DATA 0 buys · 0 sells
The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.
NEUTRAL report date 2026-10-06 · Asset managers net 906615 (+2612)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.